Background-Chronic ␤-adrenergic receptor (␤-AR) overstimulation, a hallmark of heart failure, is associated with increased cardiac expression of matrix metalloproteinases (MMPs). MMP-1 has been shown to cleave and activate the protease-activated receptor 1 (PAR1) in noncardiac cells. In the present study, we hypothesized that ␤-AR stimulation would result in MMP-dependent PAR1 transactivation in cardiac cells. Methods and Results-␤-AR stimulation of neonatal rat ventricular myocytes (NRVMs) or cardiac fibroblasts with isoproterenol transduced with an alkaline phosphatase-tagged PAR1 elicited a significant increase in alkaline phosphatase-PAR1 cleavage. This isoproterenol-dependent cleavage was significantly reduced by the broad-spectrum MMP inhibitor GM6001. Importantly, specific MMP-13 inhibitors also decreased alkaline phosphatase-PAR1 cleavage in isoproterenol-stimulated NRVMs, as well as in NRVMs stimulated with conditioned medium from isoproterenolstimulated cardiac fibroblasts. Moreover, we found that recombinant MMP-13 stimulation cleaved alkaline phosphatase-PAR1 in NRVMs at DPRS 42 2 43 FLLRN. This also led to the activation of the ERK1/2 pathway through G␣q in NRVMs and via the G␣q/ErbB receptor pathways in cardiac fibroblasts. MMP-13 elicited similar levels of ERK1/2 activation but lower levels of generation of inositol phosphates in comparison to thrombin. Finally, we demonstrated that either PAR1 genetic ablation or pharmacological inhibition of MMP-13 prevented isoproterenol-dependent cardiac dysfunction in mice. Conclusions-In this study, we demonstrate that ␤-AR stimulation leads to MMP-13 transactivation of PAR1 in both cardiac fibroblasts and cardiomyocytes and that this likely contributes to pathological activation of G␣q and ErbB receptor-dependent pathways in the heart. We propose that this mechanism may underlie the development of ␤-AR overstimulation-dependent cardiac dysfunction. (Circulation. 2012;125:2993-3003.)
S even transmembrane G protein-coupled receptors (GPCRs), such as adrenergic, angiotensin, endothelin, and serotonin receptors, have been implicated in cardiac dysfunction and hypertrophy. 1 Among the GPCR family, the protease-activated receptors (PARs) are unique because they are activated by proteolytic cleavage of their extracellular N-terminal domain, unmasking a self-encoded, tethered ligand. The PAR family is composed of 4 members, PARs 1 to 4. PAR2 is activated by various proteases such as trypsin and tryptase, and PARs 3 and 4 are activated by thrombin. 2 The high-affinity tethered ligand for PAR1 is classically unmasked by the proteolytic activity of thrombin. Thrombin stimulation of PAR1 has been shown to trigger neonatal cardiomyocyte hypertrophy and cardiac fibroblast DNA synthesis. 3, 4 Our group has recently demonstrated that whereas cardiac-restricted PAR1 overexpression led to heart failure, 5 PAR1-deficient mice were less susceptible to myocardial injury, highlighted by their reduced left ventricular dilation and superior cardiac function compared with wild-type (WT) mice after cardiac ischemia/reperfusion. 5 This finding in PAR1-deleted mice was confirmed by the cardioprotective effect of the selective PAR1 antagonist SCH79797 in a rat model of ischemia/reperfusion. 6 During ischemia, coagulation factors, such as thrombin, are known to leak through the damaged endothelial barrier, suggesting that in ischemic conditions, thrombin is initially mainly responsible for PAR1 activation in the heart. Indeed, the role of thrombin in ischemic injury was demonstrated in a rabbit model of ischemia/reperfusion in which the thrombin inhibitor hirudin significantly reduced infarct size. 7 Interestingly, thrombin is not the only protease capable of PAR1 cleavage and activation. In particular, matrix metalloproteinase (MMP) 1 has been shown to activate PAR1 in platelets, tumor cells, and endothelial cells, promoting thrombosis, tumorigenesis, or angiogenesis, respectively. 8 -10 Although a homologue of MMP-1 has not been identified in mouse or rat, MMP-13 is considered to be the major interstitial collagenase in these species. 11 MMP-13 was found to be expressed in the healthy adult mouse heart, 12 but beyond its collagen-degrading function, its role in pathological cardiac remodeling remains unexplored. Interestingly, it has been described that pressure overload, ␤ 1 -adrenergic receptor (␤-AR) overstimulation, or myocardial infarction elevates cardiac MMP-13 expression. [13] [14] [15] 
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In this study, we determined whether activation of PAR1 in cardiac cells and the heart occurs in a nonischemic pathological condition (ie, without implication of thrombin). We show that ␤-AR overstimulation leads to PAR1 cleavage and transactivation through MMP-13 in both cardiomyocytes and cardiac fibroblasts and that this ␤-AR-elicited transactivation activity can be transmitted from fibroblasts to myocytes. We propose that the MMP-13/PAR1 axis plays a critical pathophysiological role in a nonischemic model of murine heart failure.
Methods

Animals
Generation of PAR1 knockout mice was described previously. 5 Miniosmotic pumps (1007D, Alzet Corporation), delivering filtered solutions of (Ϫ)L-isoproterenol bitartrate (isoproterenol) or vehicle (0.002% ascorbic acid in saline), dose adjusted to reflect 30 mg/kg per day of (Ϫ)L-isoproterenol HCl [ie, 43.8 mg/kg per day of (Ϫ)L-isoproterenol bitartrate], were implanted in male WT or male PAR1 knockout mice (10 -12 weeks old) under anesthesia (0.75% isoflurane). WAY170523 (7.5 mg/kg) dissolved in a mixture of 5% dimethyl sulfoxide, 40% PEG-400, and 55% saline, pH 7.4, or corresponding vehicle was injected intraperitoneal once daily for 7 days. All animal procedures were performed in accordance with the guidelines of the Department of Laboratory Animal Medicine and the University Committee on Animal Resources at the University of Rochester Medical Center.
Echocardiography
Transthoracic 2-dimenisonal and M-mode echocardiography analysis was used to assess heart function in conscious mice with a VisualSonics Vevo 770 echocardiography machine equipped with a 30-MHz probe (VisualSonics) (PAR1-null mice). Echocardiography on isoproterenolϮWAY170523-treated mice was performed with a VisualSonics Vevo 2100 equipped with an 18-to 38-MHz probe (VisualSonics). Echocardiographic data from both systems were obtained and analyzed as we have described recently in detail. 16, 17 
Cardiac Fibroblast Conditioned Medium
Cardiac fibroblasts were obtained as described in the Supplemental methods and materials section. After 4 to 5 days in culture, cells were split with the use of trypsin 0.05% and plated in 12-well plates. At 80% to 90% confluence, cardiac fibroblasts were serum-starved in Dulbecco's modified Eagle's medium and 1% penicillin/streptomycin for 24 hours and stimulated for 2, 4, or 8 hours with saline or isoproterenol (5 mol/L). Conditioned media were collected and incubated with the specific MMP-13 inhibitor WAY170523 (1 mol/L), saline, and propranolol (5 mol/L) for 15 minutes and then applied on alkaline phosphatase (AP)-PAR1-transduced neonatal rat ventricular myocytes (NRVMs) for 24 hours.
PAR1 Cleavage Assay
AP activity in the cell supernatant, which is proportional to the cleavage activity, was quantified with the use of the Phospha-Light chemiluminescent reporter assay for secreted AP kit (Tropix) as described previously. 18 
MMP-13 Activity Assay
MMP-13 cardiac activity was accessed with the use of the SensoLyte 520 MMP-13 fluorometric assay kit (Anaspec). Briefly, mouse or human heart tissues were homogenized in assay buffer containing 0.1% (vol/vol) Triton X-100 and then centrifuged for 15 minutes at 10 000g at 4°C. Fifty microliters of the homogenate supernatant was incubated in a 96-well plate with the MMP-13 substrate for 30 minutes at 37°C. Fifty microliters of cardiac fibroblast supernatant was similarly used to measure MMP-13 activity in cell culture medium. SensoLyte 520 MMP-13 fluorometric assay kit was also used to determine the IC 50 value of WAY170523 for MMP-13. The fluorescence intensity was measured with a microplate reader.
Human Heart Tissue Samples
Tissue was harvested from the left ventricular free wall near the apex of 8 male patients (aged 59.6Ϯ3.1 years) in end-stage (stage D) heart failure at the time of left ventricular assist device placement (HeartMate or HeartMate II; Thoratec, Pleasanton, CA) as either destination therapy or bridge to transplantation. Samples from 4 patients each with the diagnosis of ischemic or nonischemic heart failure etiology were analyzed. Nonfailing human heart tissue was obtained from the left ventricular free wall of 3 male organ donor hearts rejected for transplantation because of physical incompatibility. Left ventricular tissue obtained from surgery was immediately frozen in liquid nitrogen and stored at Ϫ140°C. All harvest and use of human tissue procedures were performed in accordance with the National Institutes of Health and University of Rochester Medical Center institutional review board guidelines. Supplemental methods and materials can be found in the online-only Data Supplement.
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Data Analysis and Statistics
All results are expressed as meanϮSEM. Different groups were compared through 1-way ANOVA followed by the Newman-Keuls test. Comparison between 2 groups was assessed by t test. All calculations were performed with the use of the GraphPad Prism 5.0 program.
Results
␤-AR Stimulation Leads to PAR1 Cleavage in Cardiomyocytes Through MMP-13
In the heart, chronic ␤-AR stimulation is known to induce MMP expression and activity. 14 Therefore, we hypothesized that chronic ␤-AR stimulation with the agonist isoproterenol could lead to MMP-dependent (and thrombin-independent) PAR1 cleavage in cardiac cells. To test this hypothesis, we first transduced NRVMs with the AP-PAR1-expressing ad-enovirus. Compared with vehicle-treated cells, isoproterenol (10 mol/L) stimulation led to a significant 3-fold increase in N-terminal PAR1 cleavage after 24 hours of stimulation ( Figure 1A ). This isoproterenol-dependent cleavage was highly attenuated by the PAR1-specific blocking antibody H-111 (10 g/mL) that recognizes the N-terminal domain of PAR1 ( Figure IA in the online-only Data Supplement). We excluded a potential involvement of thrombin in this process because hirudin (2.5 U/mL), a specific inhibitor of thrombin, was unable to prevent the isoproterenol-dependent PAR1 cleavage ( Figure IA in the online-only Data Supplement). To assess MMP involvement in isoproterenol-induced PAR1 cleavage, we stimulated AP-PAR1-transduced NRVMs with isoproterenol in the presence of the broad-spectrum MMP inhibitor GM6001 (10 mol/L) or the endogenous tissue inhibitor of MMP, TIMP-3 (10 ng/mL). Inhibition of general MMP activity with either GM6001 or TIMP-3 significantly reduced isoproterenol-dependent PAR1 cleavage after 24 hours of stimulation ( Figure IA in the online-only Data Supplement). A prior report suggested that among MMP-1/ 2/3/7/8/9, only MMP-1 (collagenase 1) can cleave PAR1 in human cells. 8 Rodents do not express MMP-1. However, MMP-13 is considered to act as the major interstitial collagenase in these species. 11 Therefore, we sought to test our hypothesis that isoproterenol-mediated PAR1 cleavage is mediated by MMP-13 in rodent cardiac cells. Indeed, inhibition of MMP-13 activity, with the use of 2 different highly specific small-molecule MMP-13 inhibitors ( Figure 1B ), led to a significant reduction (Ϸ50%) of isoproterenol-induced PAR1 cleavage in NRVMs ( Figure 1B) . Importantly, unlike GM6001, neither of the 2 MMP-13-specific inhibitors modified the baseline cleavage observed in NRVMs ( Figure IC in the online-only Data Supplement).
Cardiac Fibroblast Conditioned Medium Elicits PAR1 Cleavage in NRVMs via MMP-13
Considering that cardiac fibroblasts are known to be a major source of MMPs in the heart, 19 we hypothesized that activated cardiac fibroblasts could release MMPs capable of cleaving both fibroblast and myocyte PAR1 in an autocrine or paracrine manner, respectively. To investigate this possibility, we first stimulated cardiac fibroblasts with vehicle or isoproterenol (10 mol/L) for 2 to 8 hours. We then collected the conditioned medium and applied it to AP-PAR1-transduced NRVMs. Importantly, we ruled out a direct effect of any residual isoproterenol contained in the conditioned medium by adding the ␤-AR antagonist propranolol (5 mol/L) before adding the conditioned medium to the NRVM culture. As shown in Figure 2A , conditioned medium obtained from nonstimulated cardiac fibroblasts increased PAR1 cleavage in NRVMs. MMP-13 does not appear to be involved in this nonstimulated conditioned medium effect because the MMP-13 inhibitor WAY170523 (1 mol/L) had no significant effect on PAR1 cleavage under these conditions. Importantly, isoproterenol conditioned medium (2, 4, and 8 hours) significantly induced PAR1 cleavage compared with nonstimulated conditioned medium (Ϸ7-fold increase with the 8-hour isoproterenol conditioned medium versus Ϸ3-fold increase for the nonstimulated conditioned medium). This isoproterenol conditioned medium-dependent cleavage is mainly mediated by MMP-13, as demonstrated by the strong reduction of PAR1 cleavage in the presence of WAY170523 ( Figure 2A ). To confirm the involvement of MMP-13 in isoproterenol-dependent cleavage of PAR1, we quantified MMP-13 activity in the conditioned medium of isoproterenolstimulated cardiac fibroblasts. Isoproterenol (10 mol/L) stimulation significantly increased MMP-13 activity after 8 hours of stimulation compared with the nonstimulated condition ( Figure 2B ).
Identification of the MMP-13 Cleavage Site in PAR1 Receptor
It has been shown previously that of several MMPs tested, human MMP-1 (collagenase 1) can cleave and activate PAR1 in human noncardiac cells. 8 -10 Furthermore, rodent MMP-13 is thought to play the role of MMP-1, which is not expressed in rodents. 11 As suggested by our data obtained with isoproterenol stimulation in NRVMs or cardiac fibroblast conditioned medium experiments, we hypothesized that MMP-13 may directly cleave PAR1. To investigate this possibility, we transduced NRVMs with the AP-tagged PAR1 adenovirus and applied different doses of recombinant MMP-13 protein to the cells. As shown in Figure 3A , MMP-13 induced a significant dose-dependent cleavage of PAR1 in NRVMs (Ͼ2-fold increase with MMP-13 40 nmol/L compared with baseline). Several proteases are known to cleave the PAR1 N-terminal domain at different sites. 20 To identify the exact MMP-13 cleavage site, we used a 26 -amino acid peptide (TR26, PAR1 residues 36 -61) corresponding to the PAR1 N-terminal domain, containing the thrombin cleavage site and flanking regions as described previously 9 ( Figure 3B ). When we incubated the TR26 peptide with thrombin, the expected cleavage peptide was obtained (residues 42-61) as determined by high-resolution mass spectrometry. However, when TR26 was incubated with MMP-13, we obtained a different peptide 43 to 61, demonstrating that MMP-13 cleaves the PAR1 N-terminal domain at a unique site, DPRS 42 2 43 FLLRN ( Figure 3B ). To functionally validate this new MMP-13 cleavage site, we transfected H9C2 cells, a myoblastic cell line originating from embryonic rat heart tissue, with WT AP-PAR1 or 3 different PAR1 mutants: an AP-R41A-PAR1 mutant that was described to be uncleavable by thrombin, 21 an AP-P40N-PAR1 mutant reported previously to be insensitive to MMP-1, 9 and an AP-F43R-PAR1 mutant in which phenylalanine in position 43 was mutated to an arginine. As shown in Figure 3C , MMP-13 (40 nmol/L)-dependent PAR1 cleavage is totally absent in the AP-R41A-PAR1-or AP-F43R PAR1-transfected cells but was similar in WT AP-PAR1-and AP-P40N-PAR1-transfected cells. Interestingly, and in contrast to a prior report, 9 we also found that thrombin (10 nmol/L)-dependent PAR1 cleavage is significantly reduced in AP-P40N-PAR1-transfected cells and to a smaller extent in AP-F43R PAR1-expressing cells ( Figure 3C ).
MMP-13 Activates PAR1 Signaling in Cardiac Cells
Although it remains somewhat unclear, some proteases, such as cathepsin G, can cleave PAR1 downstream of the putative functional SFLLRN tethered ligand. As a consequence, such proteolysis can inactivate PAR1. 22 Unlike thrombin, we found that MMP-13 cleaves PAR1 at the DPRS 42 2 43 FLLRN site. To investigate whether this new MMP-13-generated tethered ligand could activate PAR1-dependent signaling pathways, we stimulated NRVMs or cardiac fibroblasts, both of which express functional PAR1, 4 with a low dose of MMP-13 (10 nmol/L) and assessed the activation of ERK1/2. In both cell types, MMP-13 stimulation produced a significant time-dependent increase of ERK1/2 phosphorylation (4-to 6-fold increase at maximal response) ( Figure 4A and 4B ). In the presence of the selective PAR1 antagonist SCH79797 (1 mol/L), the activation of ERK1/2 was significantly decreased in either NRVMs or cardiac fibroblasts ( Figure 4A and 4B). PAR1-dependent ERK1/2 activation by MMP-13 was confirmed by the significant reduction of ERK1/2 phosphorylation in the presence of another PAR1-specific antagonist, RWJ-58259 (5 mol/L), or in the presence of the PAR1-blocking antibody S19 (15 g/mL) in NRVMs or cardiac fibroblasts, respectively ( Figure 4C and 4D) . Interestingly, the level and kinetics of MMP-13-dependent, PAR1-mediated activation of ERK1/2 were similar to those achieved by stimulation with thrombin at the same concentration (10 nmol/L and inhibited by SCH79797) in both cardiac fibroblasts ( Figure II in the online-only Data Supplement) and NRVMs. 4 Moreover, we found that the p38 mitogen-activated protein kinase was also activated by MMP-13 in a PAR1-dependent manner because SCH79797 significantly reduced p38 phosphorylation in NRVMs ( Figure  III in the online-only Data Supplement). To further demonstrate that MMP-13 activates PAR1, we measured specific PAR1 internalization in NRVMs or cardiac fibroblasts using an enzyme-linked immunosorbent assay method that quantifies PAR1 surface expression. Although not as strong as the thrombin (10 nmol/L)-dependent internalization, a significant decrease of PAR1 cell surface expression was measured in both cell types 2 hours after MMP-13 (40 nmol/L) stimulation ( Figure 5A and 5B), demonstrating that MMP-13 promoted significant PAR1 internalization in cardiac cells. Propranolol (5 mol/L) was added to the conditioned medium to prevent any direct effect of the remaining isoproterenol on NRVMs; nϭ5 independent experiments. B, ␤-adrenergic stimulation increases MMP-13 activity in cardiac fibroblast culture supernatant. A significant increase of MMP-13 activity in cardiac fibroblast supernatant is detected after 8 hours of isoproterenol (10 mol/L) stimulation; nϭ3 hearts per group; nϭ5 independent experiments. **PϽ0.05 compared with baseline; #PϽ0.05 compared with isoproterenol condition. NS indicates nonstimulated; RFU, relative fluorescence units.
PAR1 Stimulation Induces ERK1/2 via G␣q and the ErbB Receptor Pathways
Considering that PAR1 can be coupled to G␣q in heart, 4 we investigated the capacity of MMP-13 to induce ERK1/2 signaling through the G␣q pathway. We transduced cardiac fibroblasts with a green fluorescent protein (GFP)-expressing control adenovirus or with a GqI-GFP-expressing adenovirus to overexpress the GqI-GFP blocking peptide, a well-characterized competitor of endogenous G␣q proteins. 23 As shown in Figure 6A , expression of the GqI-GFP peptide in cardiac fibroblasts significantly reduced ERK1/2 phosphorylation after 5 and 10 minutes of MMP-13 stimulation ( Figure  6A ). However, late MMP-13-dependent ERK1/2 activation (20-to 30-minute time points) was not modified in the presence of the GqI-GFP peptide compared with the control GFP. To further confirm that MMP-13 leads to G␣q pathway activation, we measured the generation of inositol phosphates in cardiac cells. A prior study demonstrated that thrombin can directly activate inositol phosphate release in cardiac tissue. 24 We found that MMP-13 (40 nmol/L) stimulation elicited a statistically significant increase in inositol phosphate generation in NRVMs or cardiac fibroblasts (ϩ34% and ϩ22%, respectively), although this was considerably lower than the level of inositol phosphate generation with thrombin (10 nmol/L) ( Figure 6B ). Finally, we discovered that MMP-13 also activated ERK1/2 through transactivation of the ErbB receptor pathway in cardiac fibroblasts because the ErbB-1/4 tyrosine kinase inhibitor AG1478 (1 mol/L) significantly attenuated ERK1/2 phosphorylation at 10 and 20 minutes of MMP-13 stimulation ( Figure 6C ). However, we found that MMP-13-dependent ErbB-1/4 transactivation was specific for cardiac fibroblasts because AG1478 failed to reduce ERK1/2 phosphorylation in cardiomyocytes (data not shown).
Genetic Ablation of PAR1 or Pharmacological Inhibition of MMP-13 Prevents Isoproterenol-Induced Cardiac Dysfunction in Mice
To test whether PAR1 stimulation could be involved in pathological cardiac remodeling induced by chronic ␤-AR overstimulation, we used an acute pharmacological model of heart failure that consisted of isoproterenol infusion via osmotic pumps. We first found that MMP-13 activity is increased in hearts of WT mice infused with isoproterenol in a time-dependent manner, with a statistically significant increase at 7 days of infusion (ϩ33% compared with baseline activity) ( Figure 7A ). After performing baseline echocardiography at day 0, we infused WT and PAR1-deficient mice (PAR1 knockout) with isoproterenol for 1 week. Importantly, PAR1 knockout mice exhibited cardiac ␤-AR density similar to that of WT mice ( Figure IVA in the online-only Data Supplement). After 7 days of chronic isoproterenol infusion, the cardiac hypertrophic response was not different between PAR1 knockout and WT mice, as shown by the similar increase in the ratio of heart weight to body weight in both genotypes ( Figure IVB in the online-only Data Supplement). However, in contrast to WT mice, cardiac function measured by echocardiography was fully conserved in PAR1 knockout mice after 7 days of isoproterenol infusion ( Figure 7B ). Moreover, left ventricular systolic diameter was significantly increased in WT mice but was not modified in PAR1 knockout mice ( Figure IVC in the online-only Data Supplement). To investigate a putative role of MMP-13 in isoproterenol-dependent cardiac dysfunction, we infused WT mice with isoproterenol for 7 days and concurrently delivered the specific MMP-13 inhibitor WAY170523 daily by intraperitoneal injection. Remarkably, we found that WAY170523 completely abolished the isoproterenol-dependent increase of left ventricular systolic diameter ( Figure IVD in the onlineonly Data Supplement) and preserved cardiac function in isoproterenol-infused animals ( Figure 7C ) without modifying the hypertrophic response ( Figure IVE in the online-only Data Supplement), similar to results in the PAR1 knockout animals.
Finally, we found that MMP-13 protein expression and MMP-13 activity are significantly increased in the failing As expected, thrombin elicits a more robust and faster internalization of PAR1; nϭ5 independent experiments. B, As observed in cardiomyocytes, 2 hours of MMP-13 elicits a significant reduction of PAR1 surface expression in cardiac fibroblasts. Thrombin-dependent internalization is also faster and more robust in cardiac fibroblasts; nϭ4 independent experiments. **PϽ0.05 compared with baseline; #PϽ0.05 compared with thrombin condition.
human heart to a similar extent in nonischemic and ischemic failing tissues ( Figure 7C and 7D) .
Discussion
We have shown recently that PAR1 is involved in pathological cardiac remodeling, including an important role in myocardial ischemia/reperfusion. 5 After ischemic cardiac injury, it has been proposed that prothrombin from the blood leaks into the myocardium through the damaged endothelial barrier, and the subsequent generation of thrombin leads to pathological PAR1 signaling in the heart. 7 However, thrombin is not the only protease capable of activating PAR1, Figure 6 . Matrix metalloproteinase 13 (MMP-13)-dependent ERK1/2 activation is mediated by the G␣q and ErbBR pathways in cardiac fibroblasts. A, MMP-13 (10 nmol/L)-induced ERK1/2 phosphorylation is significantly reduced in cardiac fibroblasts transduced with the GqI-green fluorescent protein (GFP) peptide compared with cells transduced with the GFP control peptide; nϭ4 independent experiments. B, Thrombin stimulation (10 nmol/L, 1 hour) or, to a smaller extent, MMP-13 stimulation (40 nmol/L, 1hour) leads to a statistically significant increase of generation of inositol phosphates (IPs) in both cardiomyocytes and cardiac fibroblasts compared with nonstimulated cells; nϭ4 independent experiments. C, Inhibition of the ErbB receptor pathway with the AG1478 compound (1 mol/L) significantly reduces MMP-13-induced ERK1/2 phosphorylation in cardiac fibroblasts; nϭ5 independent experiments. **PϽ0.05 compared with baseline; #PϽ0.05 compared with MMP-13 alone.
suggesting that cardiac PAR1 might also be activated in nonischemic pathological conditions (ie, possibly in the absence of thrombin). Our study provides novel data that PAR1 can be cleaved and transactivated by MMP-13 on ␤-AR overstimulation, which may have pathological consequences in cardiac remodeling in vivo. We show that (1) ␤-AR stimulation leads to PAR1 cleavage and transactivation, mainly through secretion of cardiac fibroblastdependent MMP-13; (2) MMP-13 cleaves PAR1 at the DPRS 42 2 43 FLLRN site and activates PAR1 signaling in cardiac cells; and (3) genetic ablation of PAR1 or pharmacological MMP-13 inhibition protects against adrenergic overstimulation-induced cardiac dysfunction, which is associated with elevated MMP-13 expression and hyperactivity in both mouse and human heart.
The role of cardiac PAR1 activation by proteases other than thrombin is poorly understood. Recently, MMP-1-dependent PAR1 activation was found to promote invasion and tumorigenesis in human cancer cells as well as to induce arterial thrombosis via activation of platelets. 8, 9 We have identified MMP-13 as a new protease for the PAR1 N-terminal domain. Classically, the PAR1 N-terminal domain is cleaved by thrombin at the DPR 41 2 42 SFLLRN site, unmasking an SFLLRN-tethered ligand, which binds and activates PAR1. We found that MMP-13 cleaves PAR1 upstream of the thrombin site at the position Figure 7 . Protease-activated receptor 1 (PAR1) genetic ablation or pharmacological inhibition of matrix metalloproteinase 13 (MMP-13) prevents ␤-adrenergic receptor overstimulation-induced cardiac dysfunction in mice, which is associated with an increase of MMP-13 protein expression and activity in failing mouse or human heart. A, Cardiac MMP-13 activity is significantly increased after 7 days of isoproterenol infusion in mice. **PϽ0.05 compared with baseline; nϭ3 different animals. B, Fractional shortening, an index of left ventricular function, is significantly reduced in wild-type (WT) mice after 7 days (D7) of isoproterenol infusion. In contrast, cardiac function of isoproterenol-infused PAR1 knockout (KO) mice remains unaltered; nϭ6 animals in each group. **PϽ0.05, WT day 0 (D0) vs WT D7 or PAR1 KO D7 vs WT D7. C, Pharmacological inhibition of MMP-13 with WAY170523 (WAY) prevents isoproterenol (ISO)-induced cardiac dysfunction. **PϽ0.05, ISOϩvehicle (Veh) D0 vs ISOϩVeh D7 or ISOϩWAY D7 vs ISOϩVeh D7; nϭ9 and 7 animals for ISOϩVeh and ISOϩWAY, respectively. D, MMP-13 protein overexpression in failing human hearts; nϭ3 to 4 different samples per group. E, MMP-13 activity is increased in failing human hearts; nϭ3 to 4 different samples per group. **PϽ0.05 compared with nonfailing group. DPRS 42 2 43 FLLRN and observed that MMP-13 is unable to cleave the R41A or the F43R PAR1 mutants. Although the R41A mutation does not immediately flank the cleavage site, it suggests that a mutation of 1 amino acid downstream of the cleavage site would highly affect the MMP-13 cleavage efficiency. This concept is supported by the reduction of thrombin cleavage efficiency observed with the P40N mutant and to a smaller extent with the F43R PAR1 mutant. On the basis of our data, it appears that the canonical tethered ligand SFLLRN is not the only ligand capable of efficient PAR1 activation. For instance, it was shown recently that MMP-1, which does not cleave PAR1 at the thrombin site (although the exact cleavage site is still controversial 9, 25 ), can activate PAR1. Although not as efficient as a similar concentration of thrombin in terms of PAR1 cleavage, we found that 10 nmol/L of MMP-13 is sufficient to cleave PAR1 and activate PAR1-dependent signaling pathways (ERK, p38, inositol trisphosphate), demonstrating the capacity of the shorter FLLRN-tethered ligand to activate endogenous PAR1 in cardiac cells.
MMP-13 is well described to play a major role in cartilage biology. 26 In the healthy heart, MMP-13 is expressed at low levels, and its role in pathological cardiac remodeling remains largely unknown, although its cardiac expression is increased in pathological conditions. 27, 28 In the present study, we show that ␤-AR stimulation of cardiac cells transactivates PAR1 mainly through MMP-13-mediated cleavage, demonstrating the existence of a new type of protease-mediated cross-talk between a G␣s-and a G␣q-coupled receptor in heart. Indeed, on the basis of our cardiac fibroblast conditioned medium experiment, we propose that stimulation of ␤-AR on cardiac fibroblasts can lead to an MMP-13-dependent autocrine activation of PAR1 but also to the activation of the PAR1 located at the surface of the cardiomyocytes through a paracrine release of MMP-13 by cardiac fibroblasts. Confirming our data obtained at the protein level, it was described recently that ␤-AR activation leads to an increase of MMP-13 mRNA level in both adult mouse cardiac fibroblasts and cardiomyocytes. 29 It has been suggested that transactivation of ErbB receptor after GPCR stimulation could be a survival pathway in cardiomyocytes. 30 However, MMP-13 transactivates ERK1/2 through the ErbB receptor pathway in cardiac fibroblasts but not in cardiomyocytes, as described previously for thrombin PAR1-dependent activation of ERK1/2. 4 This observation suggests that MMP-13 elicits the activation of a pathological PAR1/G␣q pathway 31 without activation of a prosurvival ErbB receptor-dependent signaling in cardiomyocytes. Conversely, GPCR-dependent ErbB receptor transactivation in cardiac fibroblasts is known to lead to pathological events such as proliferation, 4,32 inflammatory cytokine release, 33 and extracellular matrix formation, 34 which are associated with cardiac dysfunction.
Conditioned medium from isoproterenol-stimulated cardiac fibroblasts leads to increased MMP-13-mediated PAR1 cleavage compared with direct isoproterenol stimulation of cardiomyocytes, suggesting that the main source of MMP-13 originates from cardiac fibroblasts. Although a MMP-13-selective inhibitor drastically attenuates isoproterenolinduced PAR1 cleavage, the inhibition is not complete. As demonstrated very recently by Lee et al 35 using a mass spectrometry approach, and diverging from the results of Boire et al, 8 MMP-3, MMP-8, and MMP-9 may also cleave PAR1 at the DPR 41 2 42 SFLLRN site (whereas MMP-1 may cleave at the D 39 2 40 PRSFLLRN site). Therefore, it is possible that the remaining isoproterenol-dependent PAR1 cleavage observed in the presence of the selective MMP-13 inhibitor is due to the activity of 1 or more of these 3 MMPs that are known to be expressed in the heart. 12 MMP-13 was described previously to induce the ERK1/2 pathway in a mouse kidney-like cell line, 36 but whether PAR1 triggers this intracellular pathway activation remains unknown. Importantly, the authors of that study experimentally ruled out the possibility that MMP-13 itself was able to cleave heparin-binding epidermal growth factor-like growth factor or transforming growth factor-␣ to subsequently induce ERK1/2 activation through epidermal growth factor receptor transactivation. In the present study, we discovered that MMP-13 leads to ERK1/2 activation mainly through direct cleavage and subsequent activation of PAR1 in primary cardiac cells, as shown by the significant decrease of MMP-13-dependent ERK1/2 activation in the presence of 2 different PAR1-specific antagonists or in the presence of a PAR1 N-terminal domain blocking antibody. Interestingly, although both thrombin and MMP-13 at the same concentration elicited similar levels of PAR1-mediated ERK1/2 activation, MMP-13 was not as robust as thrombin in the generation of inositol phosphates, suggesting a possible ligand bias of downstream PAR1 signaling by MMP-13. These data likely suggest that the generation of the FLLRN ligand by MMP-13 primarily promotes the activation of the ERK1/2 pathway. As now clearly demonstrated for GPCRs, including the angiotensin 1 receptor, 37 biased ligands can selectively activate unique intracellular pathways by promoting a specific receptor conformation. Although a detailed study is required to substantiate this possibility for PAR1, we propose that MMP-13-dependent generation of the FLLRN ligand elicits a PAR1 conformational change that is divergent from that of thrombin and that differentially activates downstream signaling pathways in terms of potency and specificity.
In pathological conditions, ␤-AR overactivation plays a critical role in the development of cardiac dysfunction. 38 The underlying mechanism(s), however, remains elusive. We propose that transactivation of pathological PAR1/G␣q signaling through MMP-13, in both cardiomyocytes and cardiac fibroblasts, participates in the establishment of ␤-AR overactivation-dependent cardiac dysfunction. Interestingly, PAR1 overactivation in human heart failure, measured by its level of phosphorylation, has been described previously in both ischemic and nonischemic failing human hearts, 39 suggesting that PAR1 is chronically activated in pathological conditions. In the present study, we described that activation of PAR1 by MMP-13 is critical for ␤-AR overactivationinduced cardiac dysfunction. Indeed, in contrast to WT mice, we found that mice with a genetic ablation of PAR1 or with a pharmacological inhibition of MMP-13 exhibit a compensated cardiac hypertrophy with no sign of cardiac dysfunction in a nonischemic model of heart failure. Because we showed that MMP-13 expression and activity are increased in either ischemic or nonischemic human failing tissue, we suggest that MMP-13 participates in pathological PAR1 signaling activation in failing human heart regardless of pathogenesis. Consequently, it is likely that MMP-13 also elicits PAR1 activation in ischemic conditions. We propose that in the early stage of an ischemic event, thrombin may be the main activator of PAR1 in the heart. However, we believe that MMP-13 primarily contributes to chronically activate deleterious PAR1-dependent pathways within the heart, leading to the maintenance and progression of pathological cardiac remodeling. Notably, MMP-13 expression and activity remain elevated months to years after ischemia (or in essentially any etiology of end-stage heart failure). Importantly, chronic heart failure of both ischemic and nonischemic etiology is accompanied by chronically elevated circulating plasma catecholamines, and we have demonstrated that activation of PAR1 by MMP-13 is critical for ␤-AR overactivation-induced cardiac dysfunction.
In summary, we demonstrate that ␤-AR overstimulation transactivates PAR1 through MMP-13 in both cardiac fibroblasts and cardiomyocytes, leading to the activation of the pathological G␣q pathway (Figure 8 ). We propose that this mechanism participates in the development of ␤-AR overactivation-dependent cardiac dysfunction. Because we found that PAR1 is involved in pathological cardiac remodeling in ischemic 5 and also now in nonischemic conditions, we believe that specific PAR1 antagonists may represent a new therapeutic paradigm to prevent or treat cardiac dysfunction. Figure 8 . Proposed mechanism by which matrix metalloproteinase 13 (MMP-13) elicits pathological protease-activated receptor 1 (PAR1) signaling transactivation on ␤-adrenergic overstimulation in the heart. Within the heart, ␤-adrenergic overstimulation leads to MMP-13 release, mainly by cardiac fibroblasts. MMP-13 subsequently cleaves and activates PAR1 expressed at the surface of cardiac fibroblasts (autocrine activation) and of cardiomyocytes (paracrine activation). As a consequence, transactivation of pathological PAR1 signaling pathways (G␣q in cardiomyocytes and both G␣q and ErbB in cardiac fibroblasts) participates in the establishment of adrenergic-dependent cardiac dysfunction. ␤-AR indicates ␤-adrenergic receptor; ErbBR, ErbB receptor.
